As non-invasive methods, the detection of serum tumor markers such as squamous cell carcinoma (SCC) antigen and carcinoembryonic antigen (CEA) is often used to monitor the effectiveness of treatment. This evidence concerns the gene CEACAM5 and neoplasm.